We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
4.50 | 0.28% | 1,640.50 | 1,640.00 | 1,640.50 | 1,656.00 | 1,635.00 | 1,642.00 | 5,918,777 | 16:29:57 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.71 | 67.54B |
Date | Subject | Author | Discuss |
---|---|---|---|
17/11/2017 18:00 | Stop talking dividends.... this company just launched 2 blockbusters! | tradermichael | |
17/11/2017 17:10 | Growing UK political risks hanging heavy over utilities. | essentialinvestor | |
17/11/2017 17:09 | Annoying really as it always can get cheaper... | mj19 | |
17/11/2017 17:01 | Mj forgive me for one post on Ng on this thread but surely that fall is way overdone. a uk interest rates are unlikely to rise dramatically in the near term B the dividend is solid C political risk seems to be discounted | atlantic57 | |
17/11/2017 16:44 | It's pay up time for years of overly generous dividends, the price for those is now reflected in the share price. | essentialinvestor | |
17/11/2017 16:40 | i know that feeling, bought national grid it tanked, bought centrica it tanked... so nothing is safe... at the moment I only hold GSK and Barc and neither is doing anything special | mj19 | |
17/11/2017 16:33 | Mj that is very helpful thanks . I am struggling to think of Uk Companies that I would invest in just at the moment | atlantic57 | |
17/11/2017 16:23 | The problem is the debt hence no bidder GlaxoSmithKline currently boasts $5.3 billion in cash in the bank -- but it also carries $24.4 billion in debt. Had Glaxo held onto its cash, it would be rich A consequence of Glaxo's weak profits is that the company's payout ratio (the percentage of Glaxo's profits that are paid out to shareholders in the form of dividends) now exceeds 200%. Put another way, for every $1 Glaxo earns in profits, the company pays its shareholders $2 in dividends -- $1 that it has, and $1 that it has to borrow. This is not a sustainable dividend policy, hence the drama but they are paying it through 2018... after that who knows.. | mj19 | |
17/11/2017 16:09 | Surely at this valuation the company would be a very tempting bid target or am I being to simplistic | atlantic57 | |
17/11/2017 15:39 | Onward and downward. Next possible support 12718 unless it want to go the 'whole hog' at 12279. GSK DAILY | bracke | |
17/11/2017 15:12 | 12.50 anyone? | bennodean | |
17/11/2017 14:53 | Even I am getting tempted now . | redips2 | |
17/11/2017 14:48 | Here we go, will it hold.. | essentialinvestor | |
17/11/2017 10:15 | Technically very oversold | juju44 | |
17/11/2017 09:57 | We avoided a test of £13 yesterday because of US market strength imv. | essentialinvestor | |
17/11/2017 09:01 | just bought some here . Fall looks overdone | juju44 | |
17/11/2017 08:59 | MJ19...bit premature? | bili1946 | |
16/11/2017 20:27 | At last we rise yeahhhhh | mj19 | |
16/11/2017 13:42 | Trelegy/closed triple, looks a great product, it's a case of whether insurers/health services will pay the price difference to simplify a medication regime. From memory trials appear to show some incremental benefit in reducing exacerbations. | essentialinvestor | |
16/11/2017 13:36 | It's giving the impression of being dragged towards £13 like some whirlpool effect, hopefully not. | essentialinvestor | |
16/11/2017 13:21 | Nope, there's clearly an agenda here. Still, can buy nice'n'cheap while it lasts. | woodhawk | |
16/11/2017 13:17 | is there no piece of good news that can make this rise. | spoole5 | |
16/11/2017 10:32 | 16th nov TraderMichael buy tp 1950p unchanged | tradermichael |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions